PLA-b-P(NAS-co-NVP) |
|
Vaxjo ID |
268 |
|
Vaccine Adjuvant Name |
PLA-b-P(NAS-co-NVP) |
|
Adjuvant VO ID |
VO_0005755
|
|
Description |
An amphiphilic block copolymer forming micelles that present antigens covalently via NAS moieties. Induces a mixed Th1/Th2 immune profile: Stimulates IFN-γ (Th1) and IL-4 (Th2) production Improves IgG1 (Th2) and IgG2a (Th1) responses |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Micelles from amphiphilic polylactide-block-poly(N-acryloxysuccinimide-co-N-vinylpyrrolidone) (PLA-b-P(NAS-co-NVP)) block copolymers of 105 nm in size were characterized and evaluated in a vaccine context. |
|
Structure |
Block copolymer: Hydrophobic core: PLA (polylactide) Hydrophilic corona: P(NAS-co-NVP), containing active ester (NAS) for protein conjugation |
|
Appearance |
Spherical micelles ~105–114 nm in size Clear dispersion in aqueous solution |
|
Preparation |
Polymer dissolved in acetonitrile Dropwise addition to water (nanoprecipitation) Proteins (e.g., p24 HIV antigen) covalently conjugated via NAS groups Purified by centrifugal filtration |
|
Dosage |
5 µg of p24 antigen per dose Subcutaneous injection on Day 0, 21, and 42 in mice |
|
Function |
Micelles from amphiphilic polylactide-block-poly(N-acryloxysuccinimide-co-N-vinylpyrrolidone) (PLA-b-P(NAS-co-NVP)) block copolymers of 105 nm in size were characterized and evaluated in a vaccine context. The micelles were non-toxic in vitro (both in dendritic cells and HeLa cells). |
|
Safety |
Well tolerated in vitro and in vivo |
| References |
Lamrayah et al., 2022: Lamrayah M, Phelip C, Coiffier C, Lacroix C, Willemin T, Trimaille T, Verrier B. A Polylactide-Based Micellar Adjuvant Improves the Intensity and Quality of Immune Response. Pharmaceutics. 2022; 14(1); . [PubMed: 35057003].
|
